Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Revamilast

Next Previous
X
Search
Drug Profile

Revamilast

Alternative Names: GRC-4039

Latest Information Update: 29 Jun 2015

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chronic obstructive pulmonary disease; Inflammation; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 30 Apr 2013 Glenmark Pharmaceuticals completes a phase II trial in Asthma in Czech Republic, India, Poland, Russia and United Kingdom (NCT01436890)
  • 31 Dec 2012 Glenmark Pharmaceuticals completes enrolment in its phase II trial for Asthma in UK, India, Poland, Russia and Czech Republic (NCT01436890)
  • 07 Aug 2012 Glenmark Pharmaceuticals completes enrolment in the phase IIb TERRA trial for Rheuamtoid arthritis in the UK, Poland, Philippines, India, and Sri Lanka (NCT01430507)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top